Log in Register
Menu

T47D/S2 Cell Line

Invented by Dr Anne Lykkesfeldt at Danish Cancer Society

Info

Catalogue Number 152109
Antigen/Gene or Protein Targets Oestrogen receptor
Parental Line T47D
Host Human
Tissue Breast
Disease Keywords Breast carcinoma
Model Tumour line
Relevance The T47D/S2 Cell line is the control cell line for the tamoxifen resistant T47D/TR-1 and T47D/TR-2 lines. Antiestrogen resistance is a major problem in breast cancer treatment. Therefore, the search for new therapeutic targets and biomarkers for antiestrogen resistance is crucial. This cell line allows the study of the mechanisms involved in tamoxifen resistant breast cancer cell growth. This is the control cell line for the tamoxifen resistant T47D/TR-1 and T47D/TR-2.
Production Details T47D/S2 cells have been established by reduction of the serum concentration to 2% fetal calf serum, in order to enable growth inhibition with tamoxifen.
Research Area Cancer, Drug Discovery & Development
Recommended Growing Conditions Phenol red free RPMI 1640 + 2% FCS + glutamax + 8µg Insulin/ml
Notes T47DS2 cells express ER alpha and progesterone receptor.

Passage 151 (AL3707, AL3708)
Cellosaurus ID CVCL_1D45

References: 6 entries

Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.

Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.

Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.

Europe PMC ID: 25885472

SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.

Europe PMC ID: 25706943

Thrane et al. 2014. Oncogene. :. PMID: 25362855.

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.

Europe PMC ID: 25362855


Add a reference

References: 6 entries

Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.

Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.

Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.

Europe PMC ID: 25885472

SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.

Europe PMC ID: 25706943

Thrane et al. 2014. Oncogene. :. PMID: 25362855.

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.

Europe PMC ID: 25362855


Add a reference

References: 6 entries

Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.

Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.

Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.

SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.

Thrane et al. 2014. Oncogene. :. PMID: 25362855.

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.


Add a reference


This reagent does not have any reviews at the moment.